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Abstract: Postmenopausal women are vulnerable to aging and oxidative stress due to reduced
estrogen. Previous studies have shown that Korean red ginseng (KRG) has beneficial effects on
aging and antioxidant capacity. Therefore, we evaluated the effects of KRG on biological aging and
antioxidant capacity in postmenopausal women. This study conducted a double-blinded, placebo-
controlled clinical trial. The participants were randomly administered KRG or a placebo, and the
following metrics were measured: mitochondria DNA (mtDNA) copy number as an indicator of
biological aging and, total antioxidant status (TAS) as a marker of antioxidant capacity. Clinical
symptoms of fatigue, as measured by the fatigue severity scale, were assessed before and after KRG
administration. There were 63 participants, of whom 33 received KRG and 30 received a placebo.
The mtDNA copy number (KRG group: 1.58 ± 2.05, placebo group: 0.28 ± 2.36, p = 0.023) and
TAS (KRG group: 0.11 ± 0.25 mmol/L, placebo group: −0.04 ± 0.16 mmol/L, p = 0.011) increased
and the fatigue severity scale (KRG group: −7 ± 12, placebo group: −1 ± 11, p = 0.033) decreased
significantly more in the KRG group than the placebo group. KRG significantly increased the mtDNA
copy number, total antioxidant status, and improved symptoms of fatigue in postmenopausal women.
Keywords: Korean red ginseng; antioxidant activity; biological aging; fatigue; postmenopausal women
1. Introduction
Ginseng was traditionally used in East Asian countries, including Korea, China, and
Japan, as a functional health food and natural therapeutic medicine, but it is increasingly
being recognized as a natural health food internationally [1,2]. Korean red ginseng (KRG),
the technical name of which is Panax ginseng Meyer, is produced by steaming and drying
fresh, unpeeled ginseng. KRG has anti-cancer and antioxidant properties and consuming
it improves immune system activity, fatigue symptoms, blood circulation, and memory
function [2].
Although no exact mechanism has been identified for the aging process in women
after menopause, several epidemiological studies have shown that there are many diseases
related to aging in postmenopausal women. In a prospective study of 12,134 Dutch women,
age-adjusted mortality increased by 2% in women who began menopause more than a
year earlier [3]. In a Korean study, Kim et al. analyzed data from the Korean National
Health and Nutrition Examination Survey and found that postmenopausal women were
1.6 times more likely to develop a metabolic syndrome than premenopausal women [4]. A
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large cohort study on women, including postmenopausal women, showed that various
metabolic parameters associated with type 2 diabetes and cardiovascular disease rates,
both of which are closely linked to oxidative stress and chronic low-grade inflammation,
dramatically increased after menopause began [5].
Mitochondrial dysfunction is associated with senescence [6]. Both mtDNA mutations
and decreases in mtDNA copy number interrupt mitochondrial function, which may lead to
aging [7,8]. In addition, free radicals accumulate in macromolecules, such as fat, DNA, and
protein, and oxidative stress leads to cellular senescence, which induces the expression of
various inflammatory cytokines and proteins, which in turn promote aging [9,10]. Previous
clinical studies of the antioxidant effects of KRG showed that antioxidant indicators such
as superoxide dismutase (SOD), glutathione peroxidase (GPx), and catalase increased in
postmenopausal women [11]. However, the measurement of these antioxidant indicators
has limitations in primary clinical settings. As the process of examination is complex and
mainly laboratory-measurable, it cannot easily be used in clinical practice. Meanwhile,
a colorimetry diagnosis technique has recently been developed for the assessment of
antioxidative activity using simple blood tests in clinical practice. This method evaluates
all antioxidative indicators, including both enzymatic and non-enzymatic molecules in the
blood, and yields total antioxidant status (TAS) [12].
Unlike previous studies, in this study, the mtDNA copy number of lymphocytes
was used to determine biological aging, and TAS was measured to evaluate antioxidant
capability with diagnostic indicators that can easily be verified in the primary clinical
setting. Furthermore, we used the Fatigue Severity Scale (FSS) questionnaire as an indicator
of clinical symptoms for fatigue. Therefore, this study aimed to investigate the effect of
KRG primarily on biological aging and antioxidant capacity, also to evaluate how it affects
clinical fatigue symptoms.
2. Materials and Methods
2.1. Study Design and Participants
This study comprised an 8-week, randomized, double-blind, placebo-controlled,
clinical trial. Participants were examined at the Severance Health Check-up, Severance
Hospital, Yonsei University Health System, in Seoul, Korea, between August 2019 and
March 2021. This study’s protocol was approved by the Institutional Review Board of
Gangnam Severance Hospital (IRB no.: 3-2019-0089) and registered at the Clinical Research
Information Service (CRIS, KCT0006506). This study was performed in compliance with
the Declaration of Helsinki.
Eligible participants were postmenopausal women aged 46–69 years who could com-
municate in Korean naturally and who were not participating in any other interventional
studies. Additionally, participants had to have no physical restrictions on movement.
Those who were excluded were current smokers; those who consumed more than 3 stan-
dard alcoholic drinks more than two days per week; who had uncontrolled hyperten-
sion, defined as systolic blood pressure (SBP) ≥ 180 mmHg or diastolic blood pressure
(DBP) ≥ 100 mmHg; who had uncontrolled diabetes mellitus, defined as having fasting
plasma glucose ≥ 200 mg/dL; who had been diagnosed with liver disease and aspartate
aminotransferase (AST) or alanine aminotransferase (ALT) levels more than three times
the upper limit; who had been diagnosed with kidney, cardiovascular, or cerebral vascular
disease; who had any form of cancer or were undergoing cancer treatment; or who were
taking other health supplements or female hormones. Written informed consent was
obtained from all patients before participation.
A total of 73 participants were enrolled in this study, 37 of whom were randomly
placed in the KRG group and 36 of whom were randomly placed in the placebo group.
During the study, 4 participants from the KRG group were excluded, 2 of whom stopped
participating for unknown reasons, 1 of whom was hospitalized to receive surgery, and 1
of whom took multivitamin supplements. Six participants were excluded from the placebo
group, 1 of whom had abdominal pain, 2 of whom had constipation, 1 of whom took
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multivitamin supplements, and 2 of whom took other red ginseng products. A total of
33 participants in the KRG group and 30 participants in the placebo group completed the
study. Figure 1 shows a flow chart for how the study was conducted.
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2.2. Randomization
Participants were randomly assigned to take a 500 mg KRG or placebo tablet four times
daily. Participants were assigned to each group in an even ratio by sequentially assigning
them in alternating order by their assignment code. These codes were generated using SAS
version 9.4 (SAS Institute, Inc., Cary, NC, USA). Both researchers and participants were
blinded to the assignments throughout the study.
2.3. Korean Red Ginseng and Placebo Supplements
Participants in the KRG group received 2 g of KRG tablet per day. The tablets contained
8.03 mg/g of ginsenoside Rb1, 3.29 mg/g of Rc, 2.80 mg/g of Rb2, 2.50 mg/g of Rg3,
1.47 mg/g of Rf, 1.29 mg/g of Re, 1.18 mg/g of Rg1, and 1.0 mg/g of Rd. The KRG
tablets were prepared by dehydrating K G extract (3 g of KRG extract per 2 g tablet). The
placebo tablets contained cornstarch and cellulose with the same flavor as the KRG tablets.
The KRG and placebo tablet were provided by the study sponsor (The Korean Society of
Ginseng, Seoul, Korea).
2.4. Data Collection
Each participant completed a questionnaire about lifestyle, medical history, and
health supplements. Self-reported cigarette smoking, alcohol consumption, and physical
activity were extracted from the questionnaires. Current alcohol consumption was defined
as drinking less than 2 cups of alcoholic beverages a day per week. Participants were
asked about their physical exercise on a weekly basis, and physical activity was defined
Nutrients 2021, 13, 3090 4 of 12
as exercising more than 3 times per week with moderate-to-vigorous intensity. Body
mass and height were measured to the nearest 0.1 kg and 0.1 cm, respectively, while
participants wore light indoor clothing and no shoes. Body mass index was defined as
the participant’s weight in kilograms divided by the square of their height in meters.
SBP and DBP were measured using the patient’s right arm with a standard mercury
sphygmomanometer (Kensei Industry Co., Ltd., Takasai Shimotsuma, Japan). Participants
were defined as having hypertension if their SBP≥ 140 mmHg, their DBP≥ 90 mmHg, they
were taking anti-hypertension medication, or they had been diagnosed with hypertension
by a physician. Participants were defined as having diabetes if their fasting plasma
glucose ≥ 126 mg/dL, their glycated hemoglobin level ≥ 6.5%, they were taking anti-
diabetes medication, or they had been diagnosed with diabetes by a physician. Participants
were defined as having dyslipidemia if their total cholesterol ≥ 240 mg/dL, low-density
lipoprotein (LDL) cholesterol ≥ 160 mg/dL, triglycerides ≥ 150 mg/dL, or high-density
lipoprotein (HDL) cholesterol < 50 mg/dL, they were taking anti-dyslipidemia medication,
or they had been diagnosed with dyslipidemia by a physician. Participants were defined
as being postmenopausal if they had not had a menstrual period for at least the preceding
12 months in the absence of a clear biological or physiological cause.
Blood samples were obtained after 8 h of overnight fasting. Leukocyte counts were
measured using an ADVIA 2120i Hematology System (Siemens Healthcare Diagnostic,
Inc., Tarrytown, NY, USA). Fasting plasma glucose, total cholesterol, triglycerides, LDL
cholesterol, HDL cholesterol, AST, ALT, and gamma-glutamyltransferase (gamma-GT)
were measured with an ADVIA 1800 Clinical Chemistry System (Siemens Healthcare
Diagnostic, Inc., Tarrytown, NY, USA).
2.5. Dependent Variable Assessment
2.5.1. Total Antioxidant Status
TAS was measured using a TBA c8000 automated colorimeter (Toshiba Medical system
Ltd., Tokyo, Japan). The antioxidative molecules in the sample reduce dark blue-green-
colored 2,2′-azinobis(3-ethylbenzo-thiazoline-6-sulfonate) radicals into a colorless form
according to antioxidant concentrations and capacities. The change in absorbance at 660 nm
is related to the total amount of antioxidants in the sample. The TAS assay was calibrated
with Trolox equivalent, a stable, standard antioxidant solution and a vitamin E analog [12].
2.5.2. Mitochondria DNA Copy Number
All DNA samples were extracted from ethylenediaminetetraacetic acid (EDTA)-treated
blood. High-quality genomic DNA was extracted from participants’ peripheral blood using
a QIAamp DNA Mini Kit (Qiagen, Valencia, CA, USA) according to the manufacturer’s
protocol. The concentration and purity of total DNA were controlled by taking absorbance
readings at 260 and 280 nm using a Nanodrop 1000 spectrophotometer (preQLab Biotechnol-
ogy, Erlangen, Germany). The relative mtDNA copy number was measured by quantitative
real-time PCR. Two pairs of primers were designed and used to quantify the mtDNA copy
number. The first primer pair was used to amplify the ND5 gene in the mtDNA.
The forward primer (ND5-F) was 5′-TTCATCCCTGTAGCATTGTTCG-3′ and the re-
verse primer (ND5-R) was 5′-GTTGGAATAGGTTGTTAGCGGTA-3′. The second primer
pair was used to amplify the nuclear DNA rRNA 18S. The forward primer (18S-F) was 5′-
GAGAAACGGCTACCACATCC-3′ and the reverse primer (18S-R) was 5′-GCCTCGAAAG
AGTCCTGTATTG-3′. Ten uL of the PCR reaction mixture for mtDNA amplification
consisted of 2 X SYBR Green Mastermix (Applied Biosystems, Waltham, MA, USA),
100 pmol/uL of ND5-F or 18S-F primer, 100 pmol/uL of ND5-R or 18S-R primer, and
10 ng of genomic DNA. The samples were heated to 95 ◦C for 10 min followed by 40 cycles
of heating to 95 ◦C for 15 s and then cooling to 55 ◦C for 1 min. Each sample was run
in triplicate in a 96-well plate with an Applied Biosystems 7300 real-time PCR system
(Applied Biosystems, Waltham, MA, USA). The relative copy number was calculated from
the threshold cycle value (∆Ct), which was defined as Ct18S–CtND5, where the mean
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amount of mtDNA = 2−∆Ct. The fold change of the mtDNA copy number was calculated as
the amount of ND5, the target gene, DNA normalized to the amount of 18S, the reference
gene, DNA in a treated sample.
2.5.3. Fatigue Severity Scale
The FSS is a popular tool for measuring fatigue symptoms [13]. It has been validated
for various diseases, such as multiple sclerosis, systemic lupus erythematosis, Parkinson’s
disease, and stroke [14–16]. It consists of 9 items, each of which can receive a score of
1–7 points. Fatigue severity is the sum of each item’s score for a total score range of 7–63
where higher scores indicate more severe fatigue symptoms.
2.6. Statistical Analyses
We analyzed the data based on the law of large numbers and the central limit theorem
because each group had at least 30 participants. The groups’ baseline characteristics were
compared using independent t-tests for continuous variables and chi-squared tests for
categorical values. We used a paired t-test to determine whether the groups’ metabolic
parameters differed after the intervention. The mean differences in changes between the
groups were compared using independent two-sample t-tests. All statistical analyses were
performed using SPSS version 25.0 for Windows (IBM, Armonk, NY, USA). All statistical
tests were two-sided and p-values < 0.05 were considered statistically significant.
3. Results
The groups’ baseline characteristics are presented in Table 1. The groups had similar
anthropometric parameters. The average age of the KRG group was 58.7 ± 4.2 years
old, and that of the placebo group was 59.7 ± 4.2 years old. There were no significant
differences between the two groups’ results in terms of SBP, DBP, waist circumference, body
mass index, fasting plasma glucose levels, triglyceride, HDL cholesterol, LDL cholesterol,
AST, ALT, gamma-GT level, mtDNA copy number, TAS, FSS, alcohol consumption rates,
physical activity rate, or prevalence of hypertension, diabetes, or dyslipidemia. However,
the KRG group’s average leukocyte count was 4890 ± 931 cells/µL, while that of the
placebo group was 5553 ± 1361 cells/µL (p = 0.027), and the KRG group’s total cholesterol
level was 230± 31 mg/dL, while that of the placebo group was 210± 41 mg/dL (p = 0.034).
Table 1. Baseline characteristics of study participants.
KRG Placebo p-Value
N 33 30
Age, years 58.7 ± 4.2 59.7 ± 4.2 0.330
SBP (mmHg) 120.7 ± 15.3 125.0 ± 11.1 0.207
DBP (mmHg) 73.0 ± 11.6 77.2 ± 7.9 0.104
Waist circumference (cm) 79.3 ± 6.9 80.9 ± 7.2 0.371
BMI (kg/m2) 23.7 ± 2.4 23.8 ± 3.1 0.844
Luekocyte count (cells/µL) 4890 ± 931 5553 ± 1361 0.027
Fasting plasma glucose (mg/dL) 95 ± 11 96 ± 17 0.831
Total cholesterol (mg/dL) 230 ± 31 210 ± 41 0.034
Triglyceride (mg/dL) 129 ± 66 116 ± 52 0.392
HDL cholesterol (mg/dL) 68 ± 16 65 ± 16 0.373
LDL cholesterol (mg/dL) 136 ± 38 124 ± 36 0.205
AST (U/L) 27 ± 8 25 ± 4 0.360
ALT (U/L) 23 ± 9 23 ± 7 0.873
Gamma-GT (U/L) 17 ± 11 16 ± 7 0.606
Alcohol consumption, n (%) 3 (9.1) 5 (16.7) 0.367
Physical activity, n (%) 17 (51.5) 10 (33.3) 0.145
HTN, n (%) 4 (12.1) 4 (13.3) 0.885
Diabetes, n (%) 1 (3.0) 2 (6.7) 0.498
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Table 1. Cont.
KRG Placebo p-Value
Dyslipidemia, n (%) 5 (15.2) 7 (23.3) 0.409
TAS (mmol/L) 1.42 ± 0.16 1.44 ± 0.14 0.690
mtDNA copy number 4.35 ± 2.54 4.70 ± 3.94 0.678
FSS 34 ± 16 32 ± 15 0.619
p-values were calculated using the independent two-sample. t-test for continuous values and the chi-square test for categorical value. KRG,
Korean red ginseng; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; AST, aspartate aminotransferase;
ALT, alanine aminotransferase; Gamma-GT, gamma-glutamyltransferase; HTN, hypertension; TAS, total anti-oxidative status; mtDNA
copy number, mitochondria DNA copy number; FSS, fatigue severity scale.
Table 2 presents the changes in the metabolic parameters in the two groups over the
course of the study. Body mass index, SBP, DBP, and hematologic parameters did not
change significantly in either group. The KRG group’s LDL cholesterol tended to decrease
from 136 ± 38 to 127 ± 34 mg/dL compared to the placebo group (p=0.067). However, the
two groups had no significant difference in mean changes of LDL cholesterol (p = 0.064).
Table 2. Changes in metabolic parameters of the KRG and placebo groups before and after 8 weeks.
KRG Placebo
Baseline 8 Weeks p-Value Baseline 8 Weeks p-Value Changedp-Value
BMI (kg/m2) 23.7 ± 2.4 23.7 ± 2.40 0.755 23.8 ± 3.1 23.9 ± 3.00 0.811
Change 0 ± 0.5 0.1 ± 0.1 0.972
SBP (mmHg) 120.7 ± 15.3 120.3 ± 14.9 0.822 125.0 ± 11.1 124.5 ± 12.7 0.819
Change −0.4 ± 9.9 −0.5 ± 11 0.973
DBP (mmHg) 73.3 ± 11.6 74.4 ± 9.3 0.255 77.2 ± 9.6 77.3 ± 7.9 0.948
Change 1.4 ± 6.7 0.1 ± 8 0.511
Luekocyte count (cells/µL) 4890 ± 931 4886 ± 1385 0.800 5553 ± 1361 5354 ± 1380 0.414
Change −4 ± 970 −199 ± 1317 0.505
Fasting plasma glucose (mg/dL) 95 ± 11 95 ± 8 0.969 96 ± 17 96 ± 16 0.736
Change 0 ± 9 0 ± 8 0.847
Total cholesterol (mg/dL) 230 ± 31 223 ± 31 0.172 210 ± 41 209 ± 44 0.773
Change −7 ± 30 −1 ± 31 0.465
Triglyceride (mg/dL) 129 ± 66 137 ± 124 0.560 116 ± 52 107 ± 44 0.258
Change 8 ± 80 −9 ± 41 0.305
HDLcholesterol (mg/dL) 68 ± 16 67 ± 16 0.549 65 ± 16 63 ± 15 0.240
Change −1 ± 7 −2 ± 8 0.619
LDL cholesterol (mg/dL) 136 ± 38 127 ± 34 0.067 124 ± 36 128 ± 42 0.414
Change −9 ± 24 4 ± 26 0.064
AST (U/L) 27 ± 8 25 ± 4 0.334 25 ± 4 27 ± 6 0.103
Change −2 ± 8 2 ± 6 0.082
ALT (U/L) 23 ± 9 22 ± 9 0.608 23 ± 7 24 ± 9 0.536
Change −1 ± 7 1 ± 10 0.414
Gamma-GT (U/L) 17 ± 11 19 ± 12 0.395 16 ± 7 16 ± 5 0.346
Change −2 ± 7 0 ± 4 0.243
p-values were calculated using the paired t-test (difference within groups after intervention). Changed p-values were calculated using
the independent two-sample t-test (mean change difference between two groups). KRG, Korean red ginseng; BMI, body mass index;
SBP, systolic blood pressure; DBP, diastolic blood pressure; AST, aspartate aminotransferase; ALT, alanine aminotransferase; Gamma-GT,
gamma-glutamyltransferase.
Table 3 presents data regarding this study’s primary variables of interest, including
antioxidant capacity and biological aging indicators. TAS increased significantly in the
KRG group, from 1.42 ± 0.16 to 1.53 ± 0.19 mmol/L (p = 0.021), but did not statistically sig-
nificantly change in the placebo group, decreasing from 1.44 ± 0.14 to 1.40 ± 0.17 mmol/L
(p = 0.258). The KRG group’s mean change in TAS of 0.11 ± 0.25 mmol/L was significantly
greater than that of the placebo group at −0.04 ± 0.16 mmol/L (p = 0.011).
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Table 3. Changes in antioxidant capacity and biological aging parameter of the KRG and placebo groups before and after
8 weeks.
KRG Placebo
Baseline 8 Weeks p-Value Baseline 8 Weeks p-Value Changedp-Value
TAS (mmol/L) 1.42 ± 0.16 1.53 ± 0.19 0.021 1.44 ± 0.14 1.40 ± 0.17 0.258
Change 0.11 ± 0.25 −0.04 ± 0.16 0.011
mtDNA copy number 4.36 ± 2.54 5.93 ± 3.33 <0.001 4.70 ± 3.94 4.98 ± 3.17 0.520
Change 1.58 ± 2.05 0.28 ± 2.36 0.023
Fold change 1.44 ± 0.46 1.15 ± 0.40 0.012
p-values were calculated using the paired t-test (difference within groups after intervention). Changed p-values were calculated using the
independent two-sample t-test (mean change difference between two groups). KRG, Korean red ginseng; TAS, total anti-oxidative status;
mtDNA copy number, mitochondria DNA copy number.
The biological indicator, mtDNA copy number was significantly higher in the KRG
group, increasing from 4.36 ± 2.54 to 5.93 ± 3.33 (p < 0.001), but not in the placebo group,
increasing from 4.70 ± 3.94 to 4.98 ± 3.17 (p = 0.520). The mean change in mtDNA copy
number was significantly different between the groups, with the KRG group’s change
being 1.58 ± 2.05 and the placebo group’s being 0.28 ± 2.36 (p = 0.023). Furthermore, the
fold change refers to the multiple when the baseline mtDNA copy number is considered to
be 1. The mtDNA copy number fold change in the KRG group was 1.44 ± 0.46, which was
significantly higher than that of the placebo group of 1.15 ± 0.40 (p = 0.012).
In addition, FSS scores decreased significantly in the KRG group from 34 ± 16 to
27 ± 14 (p = 0.002) but did not significantly change in the placebo group, decreasing from
32 ± 15 to 31 ± 16 (p = 0.861). The mean change in the KRG group’s FSS scores was
−7 ± 12, which was significantly different from that of the placebo group of −1 ± 11
(p = 0.033) (Table 4). The significant results of this study are summarized in Figure 2.
Table 4. Changes in questionnaire scores (FSS) of the KRG and placebo groups before and after 8 weeks.
KRG Placebo
Baseline 8 Weeks p-Value Baseline 8 Weeks p-Value Changedp-Value
FSS 34 ± 16 27 ± 14 0.002 32 ± 15 31 ± 16 0.861
Change −7 ± 12 −1 ± 11 0.033
p-values were calculated using the paired t-test (difference within groups after intervention). Changed p-values were calculated using the
independent two-sample t-test (mean change difference between two groups). KRG, Korean red ginseng; FSS, fatigue severity scale.
Nutrients 2021, 13, 3090 8 of 12
Nutrients 2021, 13, x FOR PEER REVIEW 8 of 12 
 
 
In addition, FSS scores decreased significantly in the KRG group from 34 ± 16 to 27 ± 
14 (p = 0.002) but did not significantly change in the placebo group, decreasing from 32 ± 
15 to 31 ± 16 (p = 0.861). The mean change in the KRG group’s FSS scores was -7 ± 12, which 
was significantly different from that of the placebo group of -1 ± 11 (p = 0.033)(Table 4). 
The significant results of this study are summarized in Figure 2. 
Table 4. Changes in questionnaire scores (FSS) of the KRG and placebo groups before and after 8 weeks. 
 
KRG Placebo  
Baseline 8 weeks p-value Baseline 8 weeks p-value 
Changed p-
value 
FSS 34 ± 16 27 ± 14 0.002 32 ± 15 31 ± 16 0.861  
Change −7 ± 12 −1 ± 11 0.033 
p-values were calculated using the paired t-test (difference within groups after intervention). Changed p-values were cal-
culated using the independent two-sample t-test (mean change difference between two groups). KRG, Korean red ginseng; 
FSS, fatigue severity scale. 
 
Figure 2. Changes in major results of the KRG and placebo groups before and after 8 weeks (bars mean standard devia-
tion): (A) Total antioxidant status; (B) mtDNA copy number; (C) Fatigue severity scale. KRG, Korean red ginseng. 
4. Discussion 
This study comprised a randomized, double-blind, placebo-controlled clinical trial to 
evaluate the effect of KRG consumption on biological aging, antioxidant capacity, and 
fatigue symptoms in postmenopausal women. We found that taking 2 g/day of KRG for 8 
weeks increased mtDNA copy number and TAS and reduced fatigue symptoms more 
than the placebo. Our findings are consistent with those of previous studies on the effec-
tiveness of KRG.  
Figure 2. Changes in major results of the KRG and placebo gr ups before and after 8 weeks (bar mean standard deviation):
(A) Total antioxidant status; (B) mtDNA copy number; (C) Fatigue severity scale. KRG, Korean red ginseng.
4. Discussion
This study comprised a randomized, double-blind, placebo-controlled clinical trial
to evaluate the effect of KRG consumption on biological aging, antioxidant capacity, and
fatigue symptoms in postmenopausal women. We found that taking 2 g/day of KRG for 8
weeks increased mtDNA copy number and TAS and reduced fatigue symptoms more than
the placebo. Our findings are consistent with those of previous studies on the effectiveness
of KRG.
First, in this study, KRG was shown to increase the mtDNA copy number more than
the placebo. A previous study showed that KRG improved exercise performance, increased
the ATP production capacity of muscle cells, and stimulated myoblast differentiation in
mice [17]. An animal study showed that the mtDNA copy number and messenger RNA
expression levels of mitochondrial biogenesis-related transcription factors increased more
in those with diabetes who took KRG than those who took a placebo [18]. A clinical trial
showed that the mtDNA copy number for men with metabolic syndromes increased when
they consumed 3 g/day of KRG and the mean change in their mtDNA copy number was
significantly higher than that of the group who consumed a placebo [19].
The following mechanism can be considered. Peroxisome proliferator-activated
receptor-gamma co-activator 1α (PGC-1α) plays a pivotal role in the regulation of mi-
tochondrial biogenesis. It activates nuclear respiratory factor (NRF)-1 and NRF-2, thereby
promoting the expression of mitochondrial transcription factor A (TFAM), which upreg-
ulates mitochondrial DNA transcription and replication [20,21]. Moreover, Kim et al.
reported that the Rg3 component in KRG increased the expression of PGC-1α, NRF-1, and
TFAM in an in vitro model [22]. Additionally, Shin et al. showed that KRG improved swim-
ming performance in mice and enhanced TFAM and NRF-1 gene expression levels [17].
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Therefore, KRG may lead to improvements in the PGC-1α-NRF1-TFAM pathway, which
contributes to the increased mtDNA copy number.
The mtDNA copy number is associated with aging and oxidative stress [6,23]. There-
fore, our result suggests that consuming KRG can increase mitochondrial functioning,
which is negatively associated with biological aging.
Second, the KRG group had significantly higher TAS levels following the intervention
than the placebo group did. Studies on the antioxidant activity of KRG in animal models
have shown that the levels of antioxidant indicators, such as SOD, GPx, and catalase,
increased and the levels of the oxidative stress marker MDA decreased [24–26]. Seo
et al. showed that postmenopausal women who took 3 g/day of KRG for 12 weeks had
significantly higher SOD levels than those who took a placebo [11]. Another clinical trial in
Korea showed that healthy adults who took 6 g/day of KRG had greater increases in GPx,
SOD, and catalase activity than those who took a placebo [27]. Our results are consistent
with these studies. However, a significant difference between this study and the mentioned
studies is that antioxidant indicators, which can easily be detected in primary care settings,
were used in this study rather than markers such as SOD, GPx, and catalase that are much
harder to detect in clinical settings. And, even if the dose and treatment duration of KRG
were lower than in previous studies, it had an effect on antioxidant capacity. Although the
antioxidant mechanism of KRG is not clearly understood, the following mechanism can be
considered. First of all, it may improve antioxidant capacity by downregulating reactive
oxygen species (ROS)-stimulated mitogen-activated protein kinase and protein kinase B
pathways that are involved in cell survival and growth [28,29]. Furthermore, KRG can
upregulate nuclear factor erythroid 2-related factor 2 (Nrf 2)-mediated expression of heme
oxygenase 1 as a ROS scavenging factor [30]. Additionally, the intracellular concentration of
glutathione (GSH) was increased and attenuated the reduction of GSH in the cell levels [31].
Third, the KRG group showed improvements in fatigue symptoms. A meta-analysis
reported that red ginseng intake does not statistically significantly reduce fatigue symp-
toms [32]. Another randomized, placebo-controlled study did not show that KRG con-
sumption resulted in a significant decrease in fatigue symptoms for the full sample, but a
subgroup analysis showed that it did for people over 50 years old with moderate fatigue
symptoms [33]. In this study, the KRG could reduce fatigue symptoms in postmenopausal
women as confirmed with statical significance after the intervention.
On the other hand, the mean LDL cholesterol levels in the KRG group decreased from
136 to 127 mg/dL, but they did not decrease in the placebo group. However, this decrease
was not statistically significant (p = 0.067). A previous study showed that administering
6 g/day of P. ginseng extract for 8 weeks decreased LDL cholesterol in males [34]. Another
clinical study with hyperlipidemic patients reported that LDL cholesterol decreased sig-
nificantly in the red ginseng (2 g/day) and placebo group, but there was no significant
difference between the two groups [35]. The subjects of that study were young, male, and
hyperlipidemic, while this study was conducted on postmenopausal women. Therefore,
this difference seems to indicate a dissimilarity in the study results. However, even though
the baseline LDL cholesterol level was in the normal range, it showed a tendency to de-
crease after the intervention in postmenopausal women. A large sample and long-term
clinical study are necessary to evaluate the effect of KRG on lipid metabolism in the future.
This study has several strengths. Most related studies used SOD, GPx, and MDA
as indicators of antioxidant capacity, but these markers are difficult to detect in general
clinical settings. We confirmed that the total antioxidant ability was increased in the KRG
group by quantitatively measuring various factors involved in antioxidant capacity in each
individual’s blood sample, differently from the previous methods. In addition, this study
showed that the mtDNA copy number, which is related to mitochondrial function, energy
metabolism, and the aging process, was enhanced, indicating that KRG might protect
against aging and increase cellular metabolism. In addition, we objectively evaluated
fatigue symptoms through validated questionnaires and showed that the KRG group’s
fatigue symptoms decreased. Finally, estrogen directly protects against mitochondrial
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apoptosis and reduces oxidative stress [36]. Thus, this study was conducted with post-
menopausal women whose biological aging would be faster and whose antioxidant activity
would be lower than that of premenopausal women because they have low estrogen. Fur-
thermore, postmenopausal women were selected as the study subjects to control the effects
of lifestyle habits such as smoking and drinking, which are relatively more linked to aging
and oxidative stress in women than in men. Therefore, it is significant that the study was
conducted on postmenopausal women with decreased estrogen levels, which is related to
the aging process and antioxidant capacity.
This study is the first randomized, double-blind, placebo-controlled study to investi-
gate the comprehensive efficacy of KRG administration on biological aging, antioxidant
activity, and clinical symptoms in Korean postmenopausal women. However, this study
also has some limitations. The first limitation is that the KRG group was administered
2 g/day of KRG for 8 weeks. Previous clinical studies that evaluated changes in mtDNA
copy number, antioxidant indicators, and clinical symptoms varied the dose of KRG from 1
to 6 g/day and the duration of administration from 2 to 12 weeks. These ranges indicate
that the dose and duration of KRG administration are not strongly agreed upon, so use of
higher doses or longer administration durations in this study may have produced different
outcomes, including LDL cholesterol. However, a daily dose of 2 g of KRG is generally
available as a healthy functional supplement in the market. Accordingly, in this study,
we selected 2 g per day, the dosage for safety KRG intake as a general health functional
food. Therefore, determining the optimal dose and duration for KRG intervention should
be further investigated in the future. The second limitation is that, although we told the
participants to keep their usual lifestyle during the clinical trial, we could not strictly con-
trol each individual’s behaviors, which could affect biological aging, antioxidant capacity,
and clinical symptoms. The third limitation is that the participants were all Korean post-
menopausal women, so the results may not be broadly generalizable to other populations,
such as men, premenopausal women, and different ethnicities.
5. Conclusions
This study examined the effects of KRG consumption on the primary outcomes for
variables of interest, which were changes in biological aging marker and antioxidant
capacity, and secondary variables of interest, which were fatigue symptoms, in Korean
postmenopausal women. The results showed that administering 2 g/day of KRG for
8 weeks increased the mtDNA copy number, increased antioxidant activity, and reduced
fatigue symptoms more than the placebo.
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